BioCardia, Inc. - Common Stock (BCDA)

Competitors to BioCardia, Inc. - Common Stock (BCDA)

Athersys, Inc.

Athersys focuses on developing its MultiStem cell therapy for a variety of conditions, including cardiovascular diseases, which puts it directly in competition with BioCardia's regenerative therapies. Both companies are vying for market share in the potentially lucrative stem cell therapy market, with Athersys having an extensive clinical development program and partnerships that enhance its product pipeline.

Celyad Oncology

Celyad focuses on a unique CAR-T cell therapy for the treatment of hematologic malignancies and is also exploring applications for cardiac conditions. Their different approach to cell therapy allows them to carve out niche opportunities that may overlap with BioCardia’s target markets, particularly in terms of leveraging advanced cellular technologies.

Mesoblast Limited 

Mesoblast is also focused on developing cell-based therapies, particularly targeting cardiac diseases and conditions related to inflammation. Given that both companies are in the field of regenerative medicine and utilize similar technology platforms, they compete for the same patient populations and clinical trial opportunities, with Mesoblast holding several key partnerships that provide it with resources and credibility in the market.

Vericel Corporation 

Vericel specializes in advanced cell therapies for the treatment of sports medicine and severe burn patients, while also exploring other uses of regenerative medicine. Although Vericel is more diversified in its offerings, its expertise in cell therapy methodologies puts it in a position to compete with BioCardia for partnerships and collaborations in the regenerative medicine space.